Lys39

Site Information
DVEAIFskYGkIAGC SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 466266
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 )
Disease tissue studied:	gastric cancer ( 7 ) , leukemia ( 11 , 12 , 13 ) , chronic myelogenous leukemia ( 11 , 12 , 13 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 ) , non-small cell lung cancer ( 2 , 5 , 8 , 9 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 5 ) , non-small cell large cell lung carcinoma ( 5 ) , non-small cell squamous cell lung carcinoma ( 9 ) , small-cell lung cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 1 , 14 ) , DMS153 (pulmonary) ( 2 ) , DMS53 (pulmonary) ( 4 ) , DMS79 (pulmonary) ( 3 ) , Jurkat (T lymphocyte) ( 6 , 14 , 15 , 16 ) , K562 (erythroid) ( 11 , 12 , 13 ) , lung ( 2 , 3 , 4 , 5 ) , MKN-45 (gastric) ( 7 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 9 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 2 ) , NCI-H209 (pulmonary) ( 2 , 3 ) , NCI-H3255 (pulmonary) ( 8 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 5 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 2 ) , SW620 (intestinal) ( 17 )

References
1	Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520 25825284 Curated Info
2	Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
11	Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
12	Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
15	Possemato A (2006) CST Curation Set: 2194; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Possemato A (2006) CST Curation Set: 2195; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
17	Li Y (2006) CST Curation Set: 1103; Year: 2006; Biosample/Treatment: cell line, SW620/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info